|
Several possibilities for the release of circulating miRNAs have been proposed as shown in Fig. 2: (1) passive leakage fromcells due to injury, chronic inflammation, or necrosis [6,7] including miR-208 [55], miR-122 [56], miR-192 [47], miR-21 [57], miR-200c [57], and miR-423 [57], which may probably release from the heart, liver and kidney due to injury, respectively. (2) Active secretion via membrane vesicles such as exosomes, L-exosome, microvesicles (MVs) and apoptotic bodies [58,59]. (3) Active secretion by complex formationwith lipoproteins (high-density lipoprotein, HDL) [60] and RNA binding proteins (AGO2 [61] and nucleophosmin 1 [62]).
Cheng, G. (2015). "Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy." Adv Drug Deliv Rev 81: 75-93.
没有具体说明 |
|